- Conditions
- Complex Regional Pain Syndrome (CRPS)
- Interventions
- Neridronic acid 100 mg, Placebo
- Drug
- Lead sponsor
- Grünenthal GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 41
- States / cities
- Cottonwood, Arizona • Tempe, Arizona • Tucson, Arizona + 34 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1585–1608
of 17,848
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatocellular Carcinoma
- Interventions
- IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg), IMC-A12 (cixutumumab) - 20 mg/kg, Sorafenib
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Chicago, Illinois + 4 more
- Conditions
- Vitreomacular Traction (VMT), Full-thickness Macular Holes (MH)
- Interventions
- Intraocular gas (C3F8)
- Device
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 45
- States / cities
- Campbell, California • Huntington Beach, California • Mountain View, California + 39 more
- Conditions
- Melanoma
- Interventions
- Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,093 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Springdale, Arkansas • Los Angeles, California + 35 more
- Conditions
- Obesity, Diabetes, Cardiovascular Diseases
- Interventions
- Exercise training
- Other
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Mucopolysaccharidosis I (MPS I)
- Interventions
- Not listed
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2024
- U.S. locations
- 53
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 44 more
- Conditions
- Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Interventions
- saracatinib, hydrocortisone/placebo
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Male only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 15
- States / cities
- Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 11 more
- Conditions
- Obesity, Diabetes Mellitus
- Interventions
- Behavioral and Drug, Behavioral
- Other
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 20 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- North Chicago, Illinois
- Conditions
- Hepatitis B
- Interventions
- JNJ-56136379, Placebo, NA (ETV or TDF)
- Drug
- Lead sponsor
- Janssen Sciences Ireland UC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 7
- States / cities
- Bakersfield, California • Orlando, Florida • Chicago, Illinois + 4 more
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- KIR genotype
- Other
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Not listed
- Enrollment
- 506 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2020
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Denver, Colorado • Atlanta, Georgia + 16 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Glimepiride, Placebo, Linagliptin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 16
- States / cities
- Chula Vista, California • Pembroke Pines, Florida • Decatur, Georgia + 11 more
- Conditions
- Obesity
- Interventions
- Cagrilintide, Semaglutide, Tirzepatide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 809 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Costa Mesa, California + 39 more
- Conditions
- Hepatocellular Carcinoma, Solid Tumor, Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent, Hepatocellular Cancer, Liver Cancer, Liver, Cancer Of, Non-Resectable
- Interventions
- OTX-2002, Tyrosine kinase inhibitor One, Tyrosine kinase inhibitor Two, Checkpoint Inhibitor, Immune
- Drug
- Lead sponsor
- Omega Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 6
- States / cities
- Duarte, California • Gainesville, Florida • Chicago, Illinois + 3 more
- Conditions
- Musculoskeletal Diseases
- Interventions
- No intervention
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 6 Months to 16 Years
- Enrollment
- 2,233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 47
- States / cities
- Hoover, Alabama • Mobile, Alabama • Phoenix, Arizona + 44 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 1
- Interventions
- liraglutide, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 4
- States / cities
- Duarte, California • Chicago, Illinois • Boston, Massachusetts + 1 more
- Conditions
- Binge Eating
- Interventions
- Go/No-Training, Stop-Signal Training, Dot-Probe Paradigm, Generic Response Training
- Behavioral
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Olaparib, Selumetinib Sulfate
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 292
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 229 more
- Conditions
- Hyperlipidemia, Dyslipidemia
- Interventions
- torcetrapib/atorvastatin, ezetimibe/simvastatin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,784 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 123
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 100 more
- Conditions
- Acute Aortic Dissection
- Interventions
- AMDS
- Device
- Lead sponsor
- Artivion Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 20 more
- Conditions
- Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Locally Advanced Merkel Cell Carcinoma, Metastatic Merkel Cell Carcinoma, Refractory Merkel Cell Carcinoma, Unresectable Merkel Cell Carcinoma
- Interventions
- Avelumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Tuvusertib
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 50
- States / cities
- Irvine, California • La Jolla, California • Los Angeles, California + 39 more
- Conditions
- Sleep Apnea, PreDiabetes, Overweight or Obesity
- Interventions
- Diet and exercise coaching, CPAP Treatment
- Behavioral · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 20 Years to 65 Years
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Enhanced Recovery After Surgery
- Interventions
- TU-100, Placebo
- Drug
- Lead sponsor
- Tsumura USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 402 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 36
- States / cities
- Florence, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 30 more
- Conditions
- High Risk Newly Diagnosed Multiple Myeloma
- Interventions
- Bispecific Monoclonal Antibody and Triplet Therapy, Monoclonal Antibody with Stem Cell Transplant
- Drug
- Lead sponsor
- Multiple Myeloma Research Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 12
- States / cities
- Duarte, California • Atlanta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Dyskinesia, Levodopa Induced Dyskinesia (LID), Parkinson's Disease (PD)
- Interventions
- ADS-5102
- Drug
- Lead sponsor
- Adamas Pharmaceuticals, Inc.
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 46 more